Abstract
Objective: To contribute toward the understanding of the therapeutic management of fallopian tube cancer. Methods: Recent studies related to the treatment of fallopian tube cancer were reviewed. Results: Current evidence indicates that even patients in early stages have nodal disease, and often experience relapses in distant sites. In advanced stages, survival prolongation by the use of platinum-based chemotherapy has been demonstrated. Aggressive cytoreductive surgery followed by chemotherapy and negative second-look laparotomy offer the possibility of long-term survival. However, a significant fraction of patients eventually relapses after negative second-look laparotomy, and a poor survival rate after positive second-look laparotomy has been observed. Conclusions: This series suggests the need for thorough evaluation of lymph nodes at the time of surgery. The use of platinum-based chemotherapy is probably the best adjuvant therapy for both early stages and advanced stages. The clinical value of second-look laparotomy will remain limited until effective salvage therapy is developed. The potential benefits of neoadjuvant chemotherapy and the use of paclitaxel will be increasingly important.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Received: August 1999 / Accepted: 23 December 1999
Rights and permissions
About this article
Cite this article
Takeshima, N., Hasumi, K. Treatment of fallopian tube cancer . Arch Gynecol Obstet 264, 13–19 (2000). https://doi.org/10.1007/PL00007475
Issue Date:
DOI: https://doi.org/10.1007/PL00007475